One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

On 1 November, the UK legalised the use of medical cannabis on prescription, but, just over one month on, medical professionals are still reluctant to prescribe the drug and restrictive guidelines have left families in need disappointed and seeking help elsewhere.

One month on: medical cannabis is still taboo despite change in law

The change in legislation has granted accessibility to cannabis-derived medicines for exceptional cases as seen in the high profile stories of Billy Caldwell and Alfie Dingley, but despite the new rules being a landmark move for UK medicine, experts argue it's not straightforward as not everyone will be granted a licence.

Under the new regulations, only specialist doctors are able to prescribe medical cannabis and those who want to obtain CBD oil for medical purposes have to apply for a licence under a temporary approval panel. Clinicians wanting to prescribe the drug have to prove exceptional clinical circumstances and need to demonstrate that there is no other lawful medicinal product that meets the specific needs of the patient.

Some 250,000 people currently use the treatment method, a number which has doubled in the last year, according to Cannabis Trades Association UK, but due to limited accessibility those in need are turning to alternative CBD oil products available on the free market.

The explosion in demand has led to huge levels of production with many companies doing so without the attention to detail or understanding required to make a product that is destined for UK consumption.

Henry Vincenty, CEO of organic CBD oil producer, Endoca, comments: “Although the change in legislation is something to celebrate, education about CBD products and the plant are still severely lacking.

“Higher demand for CBD means products which have not been standardised or have not undertaken quality testing are coming to market. What many consumers do not know is that hemp and cannabis plants are bioremediators, meaning they absorb all compounds present in the soil they are grown in - including all pesticides and heavy metals. If not quality tested and produced organically, some products can be harmful to our bodies.”

Research has found that CBD extracts can help with conditions including multiple sclerosis and nausea from cancer treatment, but most notably CBD has made huge strides with the treatment of epilepsy. There are currently 600,000 people in the UK living with epilepsy with approximately 1,000 dying from intense seizures every year. The use of CBD medicine can reduce seizures by around 50%, granting a longer and better-quality life for those affected.

Vincenty continues: “Whilst the change in UK legislation is a step in the right direction, changing the law is only half the battle. Currently there are still children and families suffering needlessly due to the denial of access.”

Related categories

Related tags

Top Stories Market News

Related news

'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more